Baseline CRP values were significantly elevated in the group that responded at 1-16 weeks compared with nonresponders [22.0 vs 3.5 mg/L, p < 0.01]. HD IFX therapy was discontinued in 26% and 7.3% of patients for inadequate response and adverse events, respectively. Eleven cases of infection required hospitalization for a serious infection rate of 7.41 events per 100 patient-years. Conclusions: HD IFX therapy may benefit CD patients who have failed standard doses of IFX. HD IFX therapy may be associated with more serious adverse events compared with standard dosing. Baseline CRP value may predict clinical response to HD IFX.
Introduction
Infliximab [IFX] is a monoclonal antibody against tumor necrosis factor alpha [TNF] used to induce and maintain remission in Crohn's disease [CD] . Failure to initially respond to IFX therapy, known as primary non-response, has been noted to occur in as many as 29-41% of patients with luminal CD [1] [2] and 31% of patients with fistulizing CD. 3 The loss of a previously achieved clinical response, known as secondary non-response, occurs by week 54 in 61% of patients receiving IFX at 5 mg/kg every 8 weeks and in 42% of patients receiving 10 mg/kg every 8 weeks. 1 One strategy for addressing primary and secondary non-response to IFX is to escalate therapy either by increasing the dosage administered or decreasing the interval between infusions. Studies examining dose escalation have demonstrated its efficacy in regaining clinical response in nonresponders and it has been suggested that IFX intensification yields more quality-adjusted life-years compared with switching to adalimumab. 66-96% among all patients who have lost response to doses of 5 mg/ kg every 8 weeks, [5] [6] [7] and one study observed the response rate to IFX escalation to be 88% in patients without antibodies to infliximab [ATI] compared with 33% among those with ATIs. 8 The sustained response rate to IFX intensification at 12 months is estimated to be 47%. 7 Current literature examining IFX dose escalation in CD has largely focussed on dose doubling from the initial regimen of 5 mg/ kg every 8 weeks to 10 mg/kg every 8 weeks or 5 mg/kg every 4 weeks. [5] [6] [7] However, a significant proportion of patients remain symptomatic despite dosing at these levels, and there are limited data on the safety and efficacy of IFX dosing above 10 mg/kg every 8 weeks or equivalent in CD. Therefore, we evaluated the efficacy, safety, and predictors of response among a group of CD patients who received 'high-dose IFX' [HD IFX] therapy, which included IFX at doses equal to or greater than 10 mg/kg every 7 weeks as maintenance therapy.
Methods

Study design and patients
We queried the electronic medical record [EPIC] to identify patients with a diagnosis of Crohn's disease according to International Classification of Diseases 555.x, who received IFX treatment between January 2010 and December 2012 at the outpatient infusion suite at the Faculty Practice Associates at Mount Sinai Medical Center, New York, NY. Patients whose primary gastroenterologists were outside the institution, who therefore had no clinical documentation in EPIC, were excluded. The remaining medical records were reviewed to stratify patients according to IFX dose. This study was approved by the Mount Sinai Institutional Review Board with a waiver of consent.
Standard dose infliximab [SD IFX] was defined as any regimen delivering less than or equal to 10 mg/kg every 8 weeks, including 5 mg/kg every 4 weeks. High-dose infliximab was defined as any regimen that delivered IFX at an average rate higher than 10 mg/ kg every 8 weeks, such as 10 mg/kg every 4 to 7 weeks, or 15 to 22.5 mg/kg every 4 to 8 weeks. The HD IFX start date was defined as the day of the first infusion of an HD IFX regimen.
Clinical evaluation included age at diagnosis and at HD IFX initiation, gender, disease location, phenotype, severity, and prior and concurrent medication use. Disease severity was assessed at HD IFX initiation, based on clinician description of symptoms, and subsequently categorized according to the American College of Gastroenterology guidelines as asymptomatic [remission] , steroid dependent, mild-to-moderate, moderate-to-severe, or severe-to-fulminant. 9 The decision to escalate to HD IFX therapy was made by the treating physician's clinical judgment on whether the patient's current therapy failed to provide adequate therapeutic response. An IFX hiatus was pre-defined as any period of 24 or more weeks without an IFX infusion after previously receiving IFX maintenance therapy, as a conservative estimate of IFX clearance. Based upon available data, clinical response was determined by the physician's assessment of symptoms at early [1-16 weeks] and late [38-100 weeks] time periods from initiation as being either full, partial, or none, indicating complete, incomplete, or lack of resolution of symptoms, respectively. Treatment failure was defined as the discontinuation of HD IFX therapy due to inadequate clinical response or due to an adverse event.
Baseline 10 A therapeutic serum IFX level was defined as greater than or equal to 3.0 µ/mL.
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Adverse events including infectious, autoimmune, and neoplastic events, as well as instances of new-onset heart failure or demyelinating disease that occurred while a patient received HD IFX, were recorded. Infusion reactions were categorized by severity as outlined by Cheifetz et al. 12 
Statistical analysis
Patients were divided according to those with and without clinical responses at the early and late time periods for further analysis. Survival analysis was conducted using length of HD IFX treatment with treatment failure as an endpoint. Adverse event rates were calculated by dividing the number of events by the total amount of time that patients received HD IFX, for which outpatient follow-up data were available.
Continuous variables were compared using a two-tailed Student's t-test. Logarithmic transformation was utilized as appropriate. Categorical variables were compared using Fisher's exact test or the chi-square test, as appropriate. Kaplan-Meier analysis with log-rank test was used to compare survival among groups with treatment failure as the endpoint. Statistical analysis was completed using Medcalc software [Mariakerke, Belgium] . A two-tailed p-value of < 0.05 was considered significant.
Results
Patients
After the screening and exclusion criteria, a total of 318 patients receiving IFX for CD were identified [ Figure 1 ]. Of these, 86 [27%] received HD IFX. Baseline characteristics are shown in Table 1 . The median age at diagnosis was 16 years and the median age at initiation of HD IFX was 28.6 years. There was a slight predominance of females at 52.3% in this population. The majority of patients had both small and large bowel disease, a history of penetrating or penetrating with fibrostenotic symptoms, and many had at least one prior hospital admission for CD. All but one patient exhibited either moderate-to-severe or steroid-dependent disease severity. Of patients with available data, receiving thiopurines, 19 of 25 patients on 6-mercaptopurine were dosed at > 1.0 mg/kg and 4 of 4 patients on azathioprine were dosed at > 2.5 mg/kg at the time of HD IFX initiation. Among all the patients, 49% had one or more previous exposures to IFX with at least a 24-week hiatus, whereas the remaining 51% had been receiving their first SD IFX induction or maintenance regimen continuously when the decision was made to escalate to HD IFX therapy.
High-dose IFX therapy
At the time of escalation to an HD IFX regimen, 13 
Therapeutic drug monitoring
Of the 86 HD IFX patients, 25 patients had serum IFX troughs drawn immediately before starting HD IFX therapy: 24 by ELISA and 1 by HMSA. Of these, 16 [64%] patients had subtherapeutic serum IFX levels less than 3.0 µg/mL, and 5 [36%] patients had therapeutic IFX levels with a median of 8.0 µg/mL [range 3.2-16.4 µg/ mL]. Among patients with available data, there were no statistically significant differences in rates of early clinical response [n = 18] or CRP improvement [n = 17] among those with subtherapeutic vs therapeutic serum IFX levels drawn immediately prior to HD IFX initiation.
A total of 10 patients had serum IFX trough levels drawn both before and after the initiation of HD IFX therapy at a median of 20.7 weeks [range 4-78 weeks]. After the initiation of HD IFX therapy, the median serum IFX trough level significantly increased from 1.7 to 7.3 µg/mL [p = 0.017], Figure 5 . Among patients with available data, there were no statistically significant differences in the rates of early clinical response [n = 9], or CRP improvement [n = 8] among those demonstrating an increase in serum IFX levels after initiating HD IFX therapy vs those who did not demonstrate an increase. 
Predictors of clinical response
24.7 kg/m 2 , p = 0.046, n = 58], though was not significantly different between responders
Safety and adverse events
Medical records were examined for safety data in 86 HD IFX patients throughout periods of compliance with therapy. A total of 148.5 patient-years were examined with a median of 64.9 [range 3.7-577] weeks of safety data per patient. Table 3 describes the adverse events experienced by patients while receiving HD IFX therapy. A total of 14 serious adverse events [requiring hospital admission or surgery] occurred in 9 patients. One death occurred in a 27-year-old female due to hemoperitoneum from necrotizing vasculitis. One month previously she underwent drainage and received antibiotics for a peritracheal abscess growing oxacillinsensitive Staphylococcus aureus. Blood and wound cultures at the time of death were negative. She had been receiving IFX at 15 mg/ kg every 4 weeks and her last infusion was 59 days before she died. Another patient who received IFX at 10 mg/kg every 4 weeks in combination with 6-mercaptopurine developed coccidioidomycosis after traveling to Arizona and was successfully treated with oral fluconazole. One other patient who received IFX at 10 mg/kg every 4 weeks in combination with azathioprine and corticosteroids developed disseminated histoplasmosis after travelling to Bangladesh. He was admitted for intravenous antifungal therapy and successfully treated; however, IFX therapy was discontinued. Vulvar squamous cell carcinoma of the skin developed in one patient with longstanding vulvar hidradenitis suppurativa, who had received IFX at 15 mg/ kg every 4 weeks in combination with tacrolimus for 178 weeks. Two other patients were diagnosed with melanoma of the skin in situ; one had received IFX 15 mg/kg every 6 weeks for 17 months, and the other had received 20 mg/kg every 4 weeks for 10 months in combination with 6-mercaptopurine. Both patients underwent successful surgical resection.
There were 59 infectious events experienced by 31 patients on HD IFX therapy. Respiratory infections were the most common [ The incidence rates of serious infections are stratified by average weekly IFX dose in Table 4 . Five serious infections occurred among five patients receiving 10 mg/kg every 4 weeks, and five serious infections occurred among two patients receiving 20 mg/kg every 4 weeks. One of the patients receiving 20 mg/kg every 4 weeks for fistulizing Crohn's disease also had axillary and perianal hidradenitis suppurativa, had declined recommended surgical therapy [diverting ostomy with wide excision] and was frequently noncompliant with prescribed medical therapy. During an 18-month period of compliance with HD IFX she experienced four serious infections: two perianal abscesses requiring drainage, one central line infection, and one pneumonia. Acute and delayed infusion reactions are shown in Table 5 . Ten patients [11.6%] experienced acute infusion reactions, nine of whom subsequently tolerated infusions after premedication with acetaminophen, steroids, and/or antihistamines. One patient receiving IFX at 15 mg/kg every 6 weeks discontinued treatment due to chest tightness and dyspnea with infusions which did not improve with premedications; this patient was subsequently switched to adalimumab. Five patients [5. 8%] experienced delayed infusion reactions, and premedications for subsequent infusions successfully prevented symptoms in four of them. One patient receiving IFX at 10 mg/kg every 7 weeks after infusions experienced headaches that were not controlled with premedications but resolved after a decrease in dosage to 5 mg/kg every 7 weeks.
Discussion
This study aims to characterize the use of HD IFX therapy for CD patients in whom standard dose therapy [up to 10 mg/kg every 8 weeks] is not adequate to control symptoms. The current literature has not explored the characteristics of patients selected to undergo high-dose infliximab escalation, or how they respond to and tolerate high-dose treatment. The present study suggests that a certain population of patients who have failed to respond, or lost response, to IFX even after standard dose escalation may benefit from further IFX dose intensification to the doses described here. The rates of clinical response we observed after escalating to an HD IFX regimen [84.9% and 62.3% at the early and late time periods, respectively] closely parallel the response rates of 66-96% seen in other studies examining standard escalation from 5 mg/kg every 8 weeks to 5 mg/ kg every 4 weeks or to 10 mg/kg every 8 weeks. [5] [6] [7] Clinical response was accompanied by a drop in inflammatory markers and was associated with a longer duration of HD IFX treatment. Furthermore, the durations of HD IFX therapy received by patients suggest that it is tolerated and represents a feasible treatment option for select patients in whom other medical options have been exhausted.
Whereas it is not fully understood why primary and secondary non-response occur in CD, investigators have proposed that free IFX concentrations may become inadequate due to altered clearance of the drug from multiple causes including the presence of antibodies to infliximab [ATIs] , and that some patients' disease may be mediated through non-TNF pathways. 13 Detectable serum trough IFX levels have been associated with improved clinical, laboratory, and endoscopic responses in a number of observational and prospective studies.
1,2,14-16 The measurement of serum IFX levels and ADA titers has been proposed to guide the decision to escalate IFX dosing or switch to another agent in the setting of non-response, 11 and the clinical significance of therapeutic drug monitoring to guide IFX dosing is under investigation. 17 In this study, we were unable to determine the ratio of primary to secondary non-responders in the HD IFX cohort due to the mixed population of both IFX-naïve and non-naïve patients and the availability of clinical data. In addition, because the clinical management of these patients was prior to the publication of the SONIC trial, only 49% of patients were receiving combination therapy before starting HD IFX. However, the incidence of primary or secondary non-response to standard IFX dosing can be approximated by examining the context in which each patient was escalated to HD IFX. Patients who were escalated to HD IFX during the first three induction doses of an SD IFX regimen likely exhibited primary nonresponse, whereas those who were escalated to HD IFX after receiving maintenance therapy with SD IFX likely exhibited secondary non-response. We found no statistical difference in clinical response rates between those who were escalated to HD IFX during the induction period vs during maintenance.
As this retrospective study was aimed at investigating the safety and efficacy of HD IFX, we recognize its limitation of few patients undergoing serum IFX and ATI measurements, since this was not considered standard practice at the time these data were collected. However, our results suggest that HD IFX escalation can significantly increase serum IFX levels, allowing for more patients to fall within the therapeutic range. Although we did not observe a statistical correlation between increased serum IFX levels and clinical or CRP response, this is likely due to the low sample size. Additionally, patients with detectable ATIs were seen to have less improvement to CRP than those without ATIs. These findings support the idea that HD IFX may have a role within the paradigm of dose escalation based on serum IFX and ATI measurements, and may be necessary to overcome drug clearance or counteract inflammatory burden in the appropriate pharmacokinetic milieu [subtherapeutic serum IFX and absent ATIs] when SD IFX is inadequate to achieve successful results.
There are limited data correlating the incidence rate of adverse events with IFX dosage or serum IFX levels. An early study examining IFX for fistulizing CD suggested an increased rate of adverse events in patients receiving scheduled treatment with 10 mg/kg vs 5 mg/kg [84% and 65%, respectively]. 18 Data from the ACCENT I trial did not suggest an increased rate of serious infections or serious events leading to discontinuation of therapy among those receiving scheduled infusions of 10 mg/kg vs 5 mg/kg. 1 Similarly, the authors of the TREAT registry note that there was no significant difference in serious infections between those receiving 10 mg/kg vs 5 mg/kg. 19 In the present study, HD IFX therapy demonstrated a high rate of adverse events compared with historical data on SD IFX therapy, although with similar rates of discontinuation due to complications from therapy. Of patients who attempted HD IFX, 7% discontinued therapy due to adverse events, which is similar to the rate of discontinuation due to reasonably related adverse events seen among SD IFX users in ACCENT I [6-8%] . 1 Although we found the rate of serious infections requiring hospitalization in patients receiving HD IFX to be increased compared with that seen among SD IFX patients in the TREAT registry, 19 this is likely confounded by the higher prevalence of more severe disease in this HD IFX cohort, which has been identified as an independent predictor of serious infections. Our sample size limits us from drawing conclusions about rare events such as malignancy.
When stratified by average weekly dose, our data suggest a positive correlation between IFX delivery and serious infections. Those receiving HD IFX at the lower end [less than 2.5 mg/kg/week] exhibit a rate of only 1.87 serious infections per 100 patient-years, similar to the rate of 2.01 serious infections per 100 patient-years seen in TREAT. Doses at these levels have also been shown to have similar serious infection rates compared with lower IFX doses and placebo in the ATTRACT trial in patients with rheumatoid arthritis. 20 The high rate of serious infections seen at the upper end of HD IFX dosages [greater than 2.5 mg/kg/week] suggests that higher IFX delivery is likely associated with more serious infections. Furthermore the fact that these events were experienced by a relatively few number of patients, with one patient accounting for 80% of serious infections in this dosage group, outlines the fact that a high degree of vigilance is necessary to identify those patients most at risk for adverse outcomes and to make appropriate accommodations when selecting a therapy. The high overall burden of complications in this population necessitates caution when prescribing IFX escalation. Furthermore, additional discretion should be exercised in geographic areas with high rates of endemic mycobacterial or fungal infections. A challenge remains to identify the patients for whom HD IFX represents the most effective and safe therapeutic option compared with other available treatments. Overall, our cohort of HD IFX patients is characterized by a high burden of disease with many patients exhibiting extensive anatomical involvement, a high prevalence of penetrating symptoms, high rates of hospitalization for CD, and a history of repeated treatment failure with other therapies. None of these factors were predictive of response to HD IFX therapy. The finding that a 24-week hiatus from IFX therapy was not associated with altered clinical response rates to HD IFX escalation suggests that HD IFX therapy may be a viable salvage treatment for patients who have previously discontinued IFX in favor of other agents, but have failed to achieve adequate control with these agents. A recent study similarly reported that re-initiation of SD IFX therapy after discontinuation due to loss of response or sustained remission is efficacious and safe. 21 The finding that a lower BMI was found among patients who responded clinically than those who did not respond is in accordance with current theories about the pharmacokinetics of serum IFX clearance.
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Inflammatory burden as approximated by CRP measurements drawn before the initiation of HD IFX therapy correlated with clinical response, with a higher baseline CRP value associated with a higher likelihood of benefitting from escalation to HD IFX therapy, reflecting similar findings as a 2011 retrospective study correlating elevated baseline CRP with increased likelihood of response to IFX. 22 Although a recent study found that higher pre-IFX CRP values were associated with a decreased likelihood of response to standard IFX dosing regimens, 23 it remains possible that patients with significant inflammatory burdens may only achieve symptom control with sufficiently high delivery of IFX that is not provided by standard dosing. IFX's intravenous administration makes it more practical to deliver these high doses than anti-TNF agents delivered subcutaneously. The decision to intensify a poorly controlled CD patient's IFX regimen or switch to another agent should be based on a combination of clinical and laboratory parameters, and through monitoring of serum IFX and ATIs. 11, 24 Similar algorithms have been proposed for adalimumab dosing as well. 25 Although the present study was limited by its retrospective nature, relatively small sample size, and limited data for IFX pharmacokinetics, it provides preliminary evidence to suggest that HD IFX may have a role in the treatment of CD. This role probably lies in patients already dose-escalated to 10 mg/kg every 8 weeks, who continue to exhibit a high CRP burden with low serum IFX levels and undetectable ATI. Given the rate of serious adverse events in this current study, HD IFX should be considered and reserved for patients with high inflammatory burden and no other therapeutic alternative. Furthermore, the significant financial costs associated with administering high doses of infliximab should be considered when deciding upon treatment. Further prospective studies and validation in large populations will help determine the optimal role of HD IFX therapy in the treatment of CD. The CCFA had no role in the study design, data collection, interpretation, writing of the manuscript, or decision to submit the manuscript for publication. Severe: significant hypo/hypertension, elevated temperature with rigors, significant shortness of breath, stridor.
